ORYZON covered for the first time by a US investment bank: ROTH Capital Partners

MADRID, SPAIN and CAMBRIDGE MA.

• ROTH’s initial equity research report sets the Company Target Price at € 15 per share

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today initiation of coverage for the first time by a US investment banking firm, ROTH Capital Partners.

Click here to see the full equity research report issued by ROTH

Click here to see the full Press Release